Cannabinoide

Vom Hanf zum Arzneimittel — eine lange Reise

Schmerzmedizin volume 33, pages34–37(2017)Cite this article

Das neue Cannabisgesetz, das Anfang 2017 in Kraft trat, ist in aller Munde. Damit soll sich die Verschreibung von cannabinoidhaltigen Arzneien und Cannabisblüten nun einfacher gestalten, bis hierhin war es allerdings ein weiter Weg.

This is a preview of subscription content, access via your institution.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abb. 1

Literatur

  1. 1.

    Maccarrone M et al. Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Rev Clin Pharmacol 2017;10(4):443–55

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Russo EB. Beyond Cannabis: Plants and the Endocannabinoid System. Trends Pharmacol Sci 2016;36:594–605

    Article  Google Scholar 

  3. 3.

    Mechoulam R et al. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci 2014;15:757–64

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Matsuda LA et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346(6284): 561–4

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Munro S et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61–5

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Devane WA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090): 1946–9

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Rinaldi-Carmona M et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350 (2-3):240–4

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Ledent C et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999;283(5400):401–4

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Maccarrone M et al. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci 2014;15:786–801

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barcelona) 2006;42(8):495–503

    CAS  Article  Google Scholar 

  11. 11.

    Ksir C, Hart CL. Cannabis and Psychosis: A critical overview of the relationship. Curr Psychiatry Rep 2016;18(2):12

    Article  PubMed  Google Scholar 

  12. 12.

    Rohleder C et al. Cannabidiol as a potential new type of an Antipsychotic. A critical review of the evidence. Front Pharmacol 2016;7:422

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Whiting PF et al. Cannabinoids for medical use: a systematic review and meta-analysis. J Am Med Ass 2015;313:2456–73

    CAS  Article  Google Scholar 

  14. 14.

    Pisanti S, Bifulco M. Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back. Trends Pharmacol Sci 2017;38:195–8

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Koppel BS et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82(17):1556–63

    Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Walitt B et al. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev 2016 Jul 18;7:CD011694

    PubMed  Google Scholar 

  17. 17.

    Smith LA et al. Cannabinoid for nausea and vomitine in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015;(11):CD009464

  18. 18.

    McLoughlin B et al. Cochrane Database Syst Rev 2014;(10):CD004837

  19. 19.

    Gloss D, Vickrey B. Cannabinoid drugs for epilepsy. Cochrane Database Syst Rev 2014;(3):CD009270

  20. 20.

    Lutge E et al. Medical use of cannabis in patients with HIV/ADIS. Cochrane Database Syst Rev 2013;(4):CD005175

  21. 21.

    Marshall K et al. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014;(12):CD008940

  22. 22.

    Zettl UK et al. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther. Adv. Neurol. Disord 2016;9(1):9–30

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Müller-Vahl K, Grotenhermen F. Medizinisches Cannabis - Die wichtigsten Änderungen. Dt Ärzteblatt 2017;114(8):A352–6

    Google Scholar 

  24. 24.

    Stott CG et al. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013;69(4):825–34

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Praxisgemeinschaft für Neurologie, Psychiatrie und Psychotherapie, Günzstr. 1, 93059, Regensburg, Deutschland

    Prof. Dr. med. Thomas Henze

Authors
  1. Prof. Dr. med. Thomas Henze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prof. Dr. med. Thomas Henze.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Henze, T. Vom Hanf zum Arzneimittel — eine lange Reise. Schmerzmed. 33, 34–37 (2017). https://doi.org/10.1007/s00940-017-0567-7

Download citation